CTNM — Contineum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855175 ·
Last close
$9.55
Market Cap
$337.62M
52W High
$17.78
52W Low
$6.72
ADV30
1,012,020
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -20,966,000 | -18,697,000 | 256,988,000 | 75,198,000 | 11,570,000 |
| Jun 2026 | 0 | — | -17,428,000 | -15,154,000 | 250,367,000 | 14,711,000 | 10,707,000 |
| Mar 2026 | 0 | — | -16,904,000 | -14,456,000 | 261,349,000 | 20,158,000 | 11,308,000 |
| Dec 2025 | 0 | — | -17,115,000 | -15,156,000 | 276,642,000 | 75,603,000 | 15,653,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,869,000
Investing CF
$-30,954,000
Financing CF
$115,388,000
CapEx
$-458,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.77
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-225,687,000
Inventory
—
Receivables
—
ST Investments
$169,286,000
EBIT TTM
$-72,413,000
Pretax Income TTM
$-63,463,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -68,059,000 | -59,978,000 | 276,642,000 | 15,653,000 | 260,989,000 | -55,312,000 |
| Dec 2024 | 0 | -50,894,000 | -42,258,000 | 212,847,000 | 14,781,000 | 198,066,000 | -32,845,000 |
| Dec 2023 | 50,000,000 | 16,077,000 | 22,720,000 | 130,386,000 | 198,322,000 | -67,936,000 | 19,349,000 |
| Dec 2022 | 0 | -22,720,000 | -24,253,000 | 50,636,000 | 143,848,000 | -93,212,000 | -20,121,000 |
TTM Snapshot
Revenues TTM
$8,814,000
NetIncome TTM
$-57,558,000
OpCashFlow TTM
—
Assets (Latest)
$250,367,000
Forward EPS
$-1.99
Max Pain — expiry 2026-12-18
max pain strike: $15.00 · spot: $9.24 · call oi: 5,068 · put oi: 288
Expected Move to 2026-12-18:
±$2.38
(25.70%) —
implied range
$6.87 –
$11.62
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | $336.08M | $13.67 | — |
| VREOF | Vireo Growth Inc. | $346.76M | $6.01 | — |
| ASPE | Aspen Neuroscience, Inc. | $348.94M | $12.00 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $321.15M | $3.01 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $318.00M | $3.96 | — |
News headlines (Yahoo Finance, 1h cache)
Qureight’s Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
2026-11-09 09:35 · Yahoo
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
2026-11-03 21:05 · Yahoo
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
2026-10-29 20:05 · Yahoo
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
2026-10-12 15:00 · Yahoo
Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
2026-10-12 12:42 · Yahoo
Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating
2026-10-12 11:55 · Yahoo
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
2026-09-24 23:04 · Yahoo
Sector Update: Healthcare Stocks Ease Late Afternoon
2026-09-15 19:52 · Yahoo
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
2026-09-14 21:32 · Yahoo
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
2026-08-25 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.